TTPH earnings call for the period ending December 31, 2018.: Tetraphase Pharmaceuticals (NASDAQ: TTPH) Q4 2018 Earnings Conference CallMarch 14, 2019 4:30 p.m. ET Good day, ladies and gentlemen, and welcome to the Tetraphase Pharmaceuticals fourth year and 2018 financial results conference call. [Operator instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Jennifer Viera, corporate communications. You may begin. Thank you. Good afternoon and thank you, everyone, for joining us on today's call.
Attune Pharmaceuticals Announces $23M Series B Financing To Advance Atn-249 For The Treatment Of Hae
NEW YORK, January 23, 2019-- Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, today announced the completion of a $23 million Series B financing. Venrock Healthcare Partners led the financing joined by new investor LifeSci Venture Partners, and existing investors RTW Investments, RA Capital, Boxer Capital and Tang Capital. In conjunction with the financing, Rod Wong, M.D., managing partner at RTW Investments, has been appointed to Attune's board of directors.
* Financing will accelerate development of the Company's cancer immunotherapy and targeted therapy programs * New brand reinforces Apollomics' mission to discover and develop novel medicines and effective combination therapies to improve the lives of cancer patients FOSTER CITY, Calif. and HANGZHOU, China, January 7, 2019-- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, today announced it has raised $100 million in a Series B financing. The financing is led by CMB International ("CMBI"), a subsidiary of China Merchants Bank, with participation from existing Series A investor OrbiMed Asia, and several new investors.
Serial entrepreneur Mike Grey is launching a biotech enterprise with $120 million in new funding to advance two investigational liver disease drugs--one of which he has worked to develop before. Called Mirum Pharmaceuticals, the startup is developing a compound, maralixibat, to treat Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), genetic liver disorders that [...]
SAN DIEGO, CA, Mirum Pharmaceuticals today announced that it has secured $120 million in Series A financing.
Dealshot: Sinopharm Capital Leads $14.6M Series A Round In Chinese Pharmaceutical Firm Eccogene - China Money Network
China Money Network's DealShot provides detailed information on venture capital and private equity deals in China on a daily basis. Here you can find out where Chinese investors have been investing their money each workday. DealShot: Sinopharm Capital Leads $14.6M Series A Round In Chinese Pharmaceutical Firm Eccogene appeared first on China Money Network.
Qiming, Hillhouse Lead $55M Series C Round In Chinese Biotech Firm Jacobio Pharmaceuticals - China Money Network
Qiming Capital and Hillhouse Capital have led a US$55 million series C round in Jacobio Pharmaceuticals, a Beijing-based clinical stage biotech company. The latest round of funding also witnessed the participation of new investor, Hong Kong-based Prudence Investment Management, according to company's announcement on official WeChat account.. Co-founded in 2015 by Wang Yinxiang, who also founded Shenzhen-listed innovative pharmaceutical company Betta Pharmaceutical, Jacobio pharmaceutical focuses on the research and development in field of cancer, autoimmune and infectious diseases. The company's most advanced program, JAB-3068, ... Qiming, Hillhouse Lead $55M Series C Round In Chinese Biotech Firm Jacobio Pharmaceuticals appeared first on China Money Network.
Suzhou-based bio-pharmaceutical company TOT Biopharm has raised US$102 million series B round led by Chinese local asset management 99Fund, according to the company's announcement. Existing investors including Centerlab Group, Vivo Capital, Chengwei Capital, Yuanda Financial Holdings, and Gold Tech Venture Capital, as well as a number of well-known investment institutions in China and abroad also participated in this round. Founded in 2010, TOT Biopharm develops, manufactures, and markets anti-tumor drugs. It specializes in therapeutic biological products, anti-tumor drugs, and specialty ... Chinese Bio-pharmaceutical Company TOT Biopharm Raises $102M Series B Round appeared first on China Money Network.
Hillhouse Capital Leads $230m Series B Preferred Stock Financing In Us Biopharmaceutical Firm Gossamer Bio - China Money Network
Hillhouse Capital has led a US$230 million series B preferred stock financing in San Diego-based biopharmaceutical firm Gossamer Bio, according to the latter's announcement. New investors participating in this financing include among others, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Invus, The Baupost Group and Polaris Partners. Gossamer Bio's existing investors, ARCH Venture Partners and Omega Funds, also meaningfully participated.
Bridge Capital Leads Series B Round In Chinese Pharmaceutical Firm Nuance Biotech - China Money Network
Nuance Biotech, a China-based specialty pharmaceutical company, today announced series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on Chinese healthcare market. Shanghai-based Nuance Biotech was co-founded by Shao Yibo, a managing partner at Matrix Partners China and also co-founder of parenting community Babytree, and Mark Lotter, an industry veteran who built the commercial operations for multinational pharmaceutical firm AstraZeneca in China, ... C-Bridge Capital Leads Series B Round In Chinese Pharmaceutical Firm Nuance Biotech appeared first on China Money Network.